{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:47:06Z","timestamp":1793677626402,"version":"4.5.1"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Career Award for Medical Scientists from the Burroughs Wellcome Fund"},{"name":"Office of the Director of the NIH","award":["DP5OD021351"],"award-info":[{"award-number":["DP5OD021351"]}]},{"name":"Junior Investigator Award from the Musculoskeletal Transplant Foundation"},{"name":"NIAMS of the NIH","award":["K23AR068447"],"award-info":[{"award-number":["K23AR068447"]}]},{"name":"NIAMS of the NIH","award":["K08AR067285"],"award-info":[{"award-number":["K08AR067285"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Disorders of bone metabolism, most notably osteoporosis, are highly prevalent and predispose to fractures, causing high patient morbidity and mortality. Diagnosis and monitoring of bone metabolic defects can present a major challenge as these disorders are largely asymptomatic and radiographic measures of bone mass respond slowly to changes in bone physiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONTENT<\/jats:title>\n                    <jats:p>Bone turnover markers (BTMs) are a series of protein or protein derivative biomarkers released during bone remodeling by osteoblasts or osteoclasts. BTMs can offer prognostic information on fracture risk that supplements radiographic measures of bone mass, but testing using BTMs has to take into account the large number of preanalytic factors and comorbid clinical conditions influencing BTM levels. BTMs respond rapidly to changes in bone physiology, therefore, they have utility in determining patient response to and compliance with therapies for osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY<\/jats:title>\n                    <jats:p>BTMs are a useful adjunct for the diagnosis and therapeutic monitoring of bone metabolic disorders, but their use has to be tempered by the known limitations in their clinical utility and preanalytic variables complicating interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1373\/clinchem.2016.259085","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T22:26:42Z","timestamp":1481322402000},"page":"464-474","source":"Crossref","is-referenced-by-count":330,"title":["Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease"],"prefix":"10.1093","volume":"63","author":[{"given":"Matthew B","family":"Greenblatt","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy N","family":"Tsai","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N","family":"Wein","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"2020022606072914700_B1","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/jbmr.499","article-title":"Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study","volume":"26","author":"Hans","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2020022606072914700_B4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s001980050164","article-title":"The relationships between the degree of beta-isomerization of type I collagen degradation products in the urine and aging, menopause and osteoporosis with fractures","volume":"9","author":"Hoshino","year":"1999","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s001980070089","article-title":"Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men","volume":"11","author":"Fall","year":"2000","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1359\/jbmr.2000.15.3.594","article-title":"Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women","volume":"15","author":"Eastell","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B8","first-page":"1505","article-title":"Urinary pyridinoline cross-links in Ehlers-Danlos syndrome type VI","volume":"57","author":"Steinmann","year":"1995","journal-title":"Am J Hum Genet"},{"key":"2020022606072914700_B9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S8756-3282(97)00105-1","article-title":"Osteoclasts generate cross-linked collagen N-telopeptides (NTX) but not free pyridinolines when cultured on human bone","volume":"21","author":"Apone","year":"1997","journal-title":"Bone"},{"key":"2020022606072914700_B10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/jbmr.5650100916","article-title":"Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods","volume":"10","author":"Kamel","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jbmr.5650110817","article-title":"Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links","volume":"11","author":"Randall","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0378-4347(92)80037-Q","article-title":"High-performance liquid chromatographic determination of 3-hydroxypyridinium derivatives as new markers of bone resorption","volume":"574","author":"Kamel","year":"1992","journal-title":"J Chromatogr"},{"key":"2020022606072914700_B13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1258\/acb.2009.009110","article-title":"Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide","volume":"47","author":"Koivula","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"2020022606072914700_B14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/clinchem\/45.7.1009","article-title":"Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women","volume":"45","author":"Kress","year":"1999","journal-title":"Clin Chem"},{"key":"2020022606072914700_B15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.cell.2011.02.004","article-title":"Endocrine regulation of male fertility by the skeleton","volume":"144","author":"Oury","year":"2011","journal-title":"Cell"},{"key":"2020022606072914700_B16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2010.06.003","article-title":"Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism","volume":"142","author":"Ferron","year":"2010","journal-title":"Cell"},{"key":"2020022606072914700_B17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cell.2013.08.042","article-title":"Maternal and offspring pools of osteocalcin influence brain development and functions","volume":"155","author":"Oury","year":"2013","journal-title":"Cell"},{"key":"2020022606072914700_B18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI112400","article-title":"Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry","volume":"77","author":"Delmas","year":"1986","journal-title":"J Clin Invest"},{"key":"2020022606072914700_B19","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1016\/S0021-9258(19)69522-0","article-title":"Developmental appearance of the vitamin K-dependent protein of bone during calcification. Analysis of mineralizing tissues in human, calf, and rat","volume":"256","author":"Price","year":"1981","journal-title":"J Biol Chem"},{"key":"2020022606072914700_B20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.7326\/0003-4819-111-12-1001","article-title":"The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion","volume":"111","author":"Knapen","year":"1989","journal-title":"Ann Intern Med"},{"key":"2020022606072914700_B21","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbrc.2010.06.008","article-title":"An ELISA-based method to quantify osteocalcin carboxylation in mice","volume":"397","author":"Ferron","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2020022606072914700_B22","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/clinchem\/41.10.1439","article-title":"Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies","volume":"41","author":"Rosenquist","year":"1995","journal-title":"Clin Chem"},{"key":"2020022606072914700_B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"2020022606072914700_B24","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","article-title":"Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis","volume":"19","author":"Szulc","year":"2008","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B25","doi-asserted-by":"crossref","first-page":"18138","DOI":"10.1038\/srep18138","article-title":"Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children","volume":"5","author":"Thiering","year":"2015","journal-title":"Sci Rep"},{"key":"2020022606072914700_B26","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of gastrointestinal hormones in postprandial reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B27","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","article-title":"Effect of feeding on bone turnover markers and its impact on biological variability of measurements","volume":"30","author":"Clowes","year":"2002","journal-title":"Bone"},{"key":"2020022606072914700_B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1556\/APhysiol.101.2014.001","article-title":"The direct effect of specific training and walking on bone metabolic markers in young adults with peak bone mass","volume":"101","author":"Gombos Cs\u00e1sz\u00e1r","year":"2014","journal-title":"Acta Physiol Hung"},{"key":"2020022606072914700_B29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2007.12.218","article-title":"Establishing a reference range for bone turnover markers in young, healthy women","volume":"42","author":"Glover","year":"2008","journal-title":"Bone"},{"key":"2020022606072914700_B30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00298428","article-title":"Urinary biochemical markers for bone resorption during the menstrual cycle","volume":"57","author":"Gorai","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2020022606072914700_B31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1359\/jbmr.1999.14.5.792","article-title":"Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices","volume":"14","author":"Woitge","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1570-0232(02)00431-2","article-title":"Acid phosphatases as markers of bone metabolism","volume":"781","author":"Igarashi","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2020022606072914700_B33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/clinchem\/46.4.469","article-title":"Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum","volume":"46","author":"Nakanishi","year":"2000","journal-title":"Clin Chem"},{"key":"2020022606072914700_B34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bonekey.2014.37","article-title":"Chronic kidney disease and osteoporosis: evaluation and management","volume":"3","author":"Miller","year":"2014","journal-title":"Bonekey Rep"},{"key":"2020022606072914700_B35","first-page":"68","article-title":"Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis","volume":"30","author":"Allanore","year":"2003","journal-title":"J Rheumatol"},{"key":"2020022606072914700_B36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am J Cardiol"},{"key":"2020022606072914700_B37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1253\/circj.71.1893","article-title":"Transient enhancement of oxidant stress and collagen turnover in patients with acute worsening of congestive heart failure","volume":"71","author":"Kunishige","year":"2007","journal-title":"Circ J"},{"key":"2020022606072914700_B38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/BF00369210","article-title":"Sexual differences in bone markers and bone mineral density of normal Chinese","volume":"59","author":"Tsai","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2020022606072914700_B39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s001980170034","article-title":"The Troms\u00f8 Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women","volume":"12","author":"Midtby","year":"2001","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2265.2002.01573.x","article-title":"Bone metabolism markers and bone mass in healthy pubertal boys and girls","volume":"57","author":"van Coeverden","year":"2002","journal-title":"Clin Endocrinol"},{"key":"2020022606072914700_B42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinchem\/48.2.315","article-title":"Collagen markers deoxypyridinoline and hydroxylysine glycosides: pediatric reference data and use for growth prediction in growth hormone-deficient children","volume":"48","author":"Rauch","year":"2002","journal-title":"Clin Chem"},{"key":"2020022606072914700_B43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cca.2008.03.020","article-title":"The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review","volume":"393","author":"Herrmann","year":"2008","journal-title":"Clin Chim Acta"},{"key":"2020022606072914700_B44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1359\/JBMR.050609","article-title":"Identification of osteopenic women at high risk of fracture: the OFELY study","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone"},{"key":"2020022606072914700_B46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrrheum.2014.23","article-title":"High-resolution in vivo imaging of bone and joints: a window to microarchitecture","volume":"10","author":"Geusens","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2020022606072914700_B47","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1210\/jc.2012-4113","article-title":"Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity","volume":"98","author":"Sowers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022606072914700_B48","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1359\/jbmr.1999.14.8.1404","article-title":"Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures","volume":"14","author":"Bauer","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18110","article-title":"Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups","volume":"18","author":"Burch","year":"2014","journal-title":"Health Technol Assess"},{"key":"2020022606072914700_B50","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1210\/jc.2015-4262","article-title":"Quantifying the balance between total bone formation and total bone resorption: an index of net none formation","volume":"101","author":"Shieh","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022606072914700_B51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1359\/JBMR.0301244","article-title":"Biochemical markers of bone metabolism and prediction of fracture in elderly women","volume":"19","author":"Gerdhem","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B52","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1210\/jc.2010-2878","article-title":"Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study","volume":"96","author":"Robinson-Cohen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022606072914700_B53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00223-008-9195-5","article-title":"Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes","volume":"84","author":"Vestergaard","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"2020022606072914700_B54","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/B978-0-12-415853-5.00067-4","article-title":"Biochemical markers of bone turnover in osteoporosis","volume-title":"Osteoporosis","author":"Szulc","year":"2013","edition":"4th ed"},{"key":"2020022606072914700_B55","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022606072914700_B56","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jbmr.341","article-title":"Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B57","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"key":"2020022606072914700_B58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"2020022606072914700_B59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"2020022606072914700_B60","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2020022606072914700_B61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"2020022606072914700_B63","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-010-1379-y","article-title":"Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide","volume":"22","author":"Blumsohn","year":"2011","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B64","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B65","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","article-title":"PINP as an aid for monitoring patients treated with teriparatide","volume":"48","author":"Tsujimoto","year":"2011","journal-title":"Bone"},{"key":"2020022606072914700_B66","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B68","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B69","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1359\/jbmr.07090b","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B70","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s001980170020","article-title":"Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis","volume":"12","author":"Bjarnason","year":"2001","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B71","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1359\/JBMR.0301243","article-title":"Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk","volume":"19","author":"Sarkar","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B72","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.1644","article-title":"Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Jacques","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B73","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/jbmr.1864","article-title":"BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate","volume":"28","author":"McNabb","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2020022606072914700_B74","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2020022606072914700_B75","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2020022606072914700_B76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.09580911","article-title":"PTH\u2013a particularly tricky hormone: why measure it at all in kidney patients?","volume":"8","author":"Garrett","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020022606072914700_B77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2020022606072914700_B78","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2020022606072914700_B79","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/clinchem\/41.10.1489","article-title":"Biochemical markers of bone turnover in patients with metastatic bone disease","volume":"41","author":"Demers","year":"1995","journal-title":"Clin Chem"},{"key":"2020022606072914700_B80","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0609.2010.01417.x","article-title":"Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis","volume":"84","author":"Lund","year":"2010","journal-title":"Eur J Haematol"},{"key":"2020022606072914700_B81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"2020022606072914700_B82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2020022606072914700_B83","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-011-1684-0","article-title":"Osteoid osteoma is an osteocalcinoma affecting glucose metabolism","volume":"23","author":"Confavreux","year":"2012","journal-title":"Osteoporos Int"},{"key":"2020022606072914700_B84","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000113063","article-title":"Serum bone turnover markers in patients with primary bone tumors","volume":"72","author":"Wang","year":"2007","journal-title":"Oncology"},{"key":"2020022606072914700_B85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S8756-3282(98)00193-8","article-title":"Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products","volume":"24","author":"Garnero","year":"1999","journal-title":"Bone"},{"key":"2020022606072914700_B86","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/art.10616","article-title":"Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study","volume":"46","author":"Garnero","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2020022606072914700_B87","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3899\/jrheum.121392","article-title":"Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis","volume":"40","author":"Krabben","year":"2013","journal-title":"J Rheumatol"},{"key":"2020022606072914700_B88","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","volume":"67","author":"Chopin","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2020022606072914700_B89","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar2219","article-title":"A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab","volume":"9","author":"Marotte","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2020022606072914700_B90","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/rheumatology\/keh072","article-title":"Bone turnover in untreated polymyalgia rheumatica","volume":"43","author":"Barnes","year":"2004","journal-title":"Rheumatology"},{"key":"2020022606072914700_B91","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3899\/jrheum.140223","article-title":"Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy","volume":"42","author":"Jadon","year":"2015","journal-title":"J Rheumatol"},{"key":"2020022606072914700_B92","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1196\/annals.1346.016","article-title":"Paget's disease of bone and genetic disorders of RANKL\/OPG\/RANK\/NF-kappaB signaling","volume":"1068","author":"Whyte","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"2020022606072914700_B93","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00198-015-3095-0","article-title":"Bone turnover markers in Paget's disease of the bone: a systematic review and meta-analysis","volume":"26","author":"Al Nofal","year":"2015","journal-title":"Osteoporos Int"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/63\/2\/464\/32646297\/clinchem0464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/63\/2\/464\/32646297\/clinchem0464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T16:36:52Z","timestamp":1657989412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/63\/2\/464\/5612856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,1]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2016.259085","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2017,2,1]]}}}